Bullish
Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts
Verrica Pharmaceuticals Inc. has dosed the first US patient in its second Phase 3 clinical trial (COVE-3) for YCANTH (VP-102) to treat common warts, w...